Dupixent® Lawsuit Attorneys

Skin Cancer & CTCL Claims

Were you or a loved one diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after using Dupixent® (dupilumab)? You may be entitled to compensation.

The law firm of Salenger, Sack, Kimmel & Bavaro, LLP is now investigating Dupixent lawsuits on behalf of patients who developed or saw worsening symptoms of CTCL after taking this widely prescribed medication.

Contact us today for a free case review or call (800) 675-8556.

What Is Dupixent (dupilumab)?

Dupixent (dupilumab) is an injectable prescription drug approved by the FDA to treat:

• Moderate to severe eczema (atopic dermatitis)
• Asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis

It was developed by Sanofi and Regeneron and works by blocking proteins that cause inflammation. While effective for many, studies and case reports now link Dupixent to skin cancers such as Cutaneous T-Cell Lymphoma.

Dupixent and Cutaneous T-Cell Lymphoma (CTCL)

CTCL is a rare, aggressive cancer of the immune system that often appears on the skin. Research suggests Dupixent may trigger or worsen CTCL, particularly in patients misdiagnosed with eczema before their lymphoma was detected.

Common CTCL symptoms include:

• Red, scaly patches or plaques on the skin
• Persistent rashes or lesions that worsen over time
• Swollen lymph nodes
• Fatigue, itching, or unexplained weight loss

For background on CTCL, visit the National Cancer Institute (NCI).

Scientific Research Linking Dupixent to CTCL

Recent peer-reviewed studies highlight the risks:

• Hasan et al., 2024 (JAMA Dermatology): Dupilumab users had a 300% higher risk of CTCL compared to non-users. Read abstract here.
• Mandel et al., 2024: Found a 350% increased risk of CTCL using large-scale TriNetX data.
• Ma et al., 2025: Dupixent users had a 4.5x higher risk of CTCL and over 14x higher risk of broader T-cell lymphomas.
• Journal of the American Academy of Dermatology (2019): Reported that Dupixent may “unmask” undiagnosed lymphomas.

These findings have prompted calls for increased patient monitoring and cautious prescribing.

Contact Us Today for a FREE Consultation

If you or a loved one has experienced health complications due to Dupixent, don’t wait to seek legal help.

Contact Salenger, Sack, Kimmel & Bavaro today for a FREE consultation.

Call (800) 675-8556 or contact us online to get started. 

Why Are Dupixent Lawsuits Being Filed?

Current lawsuits allege that Sanofi and Regeneron:

• Failed to provide adequate warnings about cancer risks
• Allowed patients to continue treatment even as cancers progressed
• Delayed label updates despite mounting medical evidence

Legal actions are in the early stages, but claims are expected to rise. No class action exists yet, though an MDL (multidistrict litigation) may form if enough cases are filed.

Who Qualifies for a Dupixent Lawsuit?

You may qualify if you:

• Used Dupixent (dupilumab) as prescribed
• Were diagnosed with Cutaneous T-Cell Lymphoma or a related lymphoma (mycosis fungoides, Sézary syndrome, etc.)
• Experienced worsening side effects while on the drug
• File within your state’s statute of limitations

👉 Even if you’re unsure, a free case evaluation can confirm your eligibility.

What Compensation May Cover

Successful claims may provide damages for:

• Past and future medical costs
• Lost wages and reduced earning ability
• Pain and suffering
• Wrongful death (if a loved one passed away)
• Punitive damages for corporate negligence

Why Choose Salenger, Sack, Kimmel & Bavaro

• Decades of success in dangerous drug and product liability lawsuits
• No upfront fees – we only get paid if you win
• Access to top medical experts in oncology and dermatology
• Compassionate, personalized legal support for every client

Frequently Asked Questions (FAQs) About The Dupixent Lawsuit

Does Dupixent cause cancer?
Research has linked Dupixent (dupilumab) to an increased risk of Cutaneous T-Cell Lymphoma (CTCL), a rare type of skin cancer. Studies published in JAMA Dermatology (2024) and JAAD (2019) reported significantly higher CTCL risks among Dupixent users.

Is there a Dupixent lawsuit?
Yes. Lawsuits are being filed against Sanofi and Regeneron, alleging they failed to warn patients about the risk of CTCL and other lymphomas.

What cancers are linked to Dupixent?
The strongest evidence links Dupixent to Cutaneous T-Cell Lymphoma (CTCL), including subtypes like mycosis fungoides and Sézary syndrome. Some studies suggest an increased risk of other T-cell and NK-cell lymphomas as well.

Has Dupixent been recalled?
As of now, Dupixent has not been recalled by the FDA, but warnings have been updated as new research emerges.

Am I eligible for a Dupixent lawsuit?
You may qualify if you:

• Took Dupixent (as prescribed)

• Were later diagnosed with CTCL or another T-cell lymphoma

• File your claim within your state’s statute of limitations

What compensation can I recover in a Dupixent lawsuit?
Potential damages include medical costs, lost wages, pain and suffering, and in severe cases, wrongful death compensation.

Take Action Now

If Dupixent caused you or a loved one to develop CTCL or another T-cell lymphoma, don’t wait. Legal deadlines apply, and acting quickly protects your rights.

📞 Call (800) 675-8556 or fill out our online form today for a free, confidential consultation.